MetrioPharm News 03/2017

MetrioPharm Announces Positive Top Line Results from a Phase IIa Study in Moderate-to-Severe Psoriasis with its Oral Lead Compound MP1032 Based on these positive results, MetrioPharm plans to move its MP1032 program forward into a phase IIb study in moderate-to-severe psoriasis. Zurich, March 14, 2017. MetrioPharm AG, a biotech company developing small molecule immune...

Learn More

MetrioPharm News 02/2017

MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032 to Japan Zurich, February 14, 2017. MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in Japan. This expands the list of countries in which MetrioPharm has broad protection for MP1032 from Europe, the USA, Australia, New Zealand, Israel, China, Russia, and South...

Learn More

MetrioPharm News 10/2016

Recruiting of MP1032’s Phase IIa trial in psoriasis successfully completed Zurich, October 25, 2016. MetrioPharm AG announces that dosing of the last patient in the clinical phase IIa trial MP1032-CT02 was started on October 20, 2016. The enrolment of the last patient marks the successful completion of the recruitment phase. Even though the study is not completed...

Learn More

MetrioPharm News 09/2016

  Capital Increase of MetrioPharm AG on 05-Sep-2016 On 05 September 2016, MetrioPharm carried out a capital increase on the basis of exercised subscription rights and issued 910,000 new shares at a subscription price of CHF 0.90. The subscription rights of the existing shareholders were granted through this small capital increase. Thus, MetrioPharm AG is now able to...

Learn More

MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032

Zurich, August 03, 2016. MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in two additional countries. This expands the list of countries in which MetrioPharm has broad protection for MP1032 from Europe, the USA, Australia, New Zealand, Israel, and China to further include Russia and South Africa. The Russian Patent No. RU2585677C2...

Learn More

MetrioPharm AG Reinforces its Management and Board for Further Growth

Zurich, 29-Jun-2016. Today, MetrioPharm AG announces that Dr. Sylvie Grégoire has been elected as the new Executive President of MetrioPharm’s Board of Directors at the company’s 10th Annual General Meeting. Dr. Wolfgang Brysch, who held this position before, will become new CEO of MetrioPharm AG ensuring continuity with the successful founders’ management...

Learn More

MetrioPharm: Go-Ahead for the Clinical Phase II Trial

Zurich, May 03, 2016. MetrioPharm AG announces the start of the clinical phase IIa trial in moderate-to-severe psoriasis for its lead molecule MP1032. After receiving approval from the German Federal Institute for Drugs and Medical Devices (BfArM) for the clinical phase IIa study, the first study site will open next week. From that day on, psoriasis patients can be...

Learn More

MetrioPharm: New basic patents granted

Zurich, March 29, 2016. MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in two additional countries. This expands the list of countries in which MP1032 is exclusively protected from Europe, the USA, Australia, and New Zealand, to Israel and China. The Israeli Patent No. 221680 was effectively granted on December 25, 2015. The...

Learn More

MetrioPharm: Phase I successfully completed

Zurich, Dec. 16. 2015 MetrioPharm AG today announced positive results for all end points of its placebo controlled phase Ib clinical trial of the company’s lead drug MP1032. No toxicity or any other drug-related adverse reactions were seen in any of the healthy study subjects up to the maximum dose of 300 mg twice a day for seven days. The positive study results enable...

Learn More

Metriopharm: Second part of Phase I Safety Study cleared by authorities

Berlin/Zurich, October 19, 2015: Following the completion of the single-dose segment in the MP1032 Phase I first-in-man study, the clinical and safety data from this trial were submitted by MetrioPharm to the German regulatory authority (BfArM) for a safety review. Safety is the paramount concern during any first-in-man study and thus BfArM performs an interim review...

Learn More

MetrioPharm AG announces the start of phase 1 clinical trial with a novel macrophage modulator

Metriopharm announced today that the Phase 1 clinical trial of its lead compound MP1032 has now commenced with the dosing of the first group of subjects. Four groups of healthy volunteers are receiving single rising doses of MP1032 in a German clinical trial site. This first-in-man study is designed to evaluate the safety and tolerability of orally administered...

Learn More

MetrioPharm – Patents

MetrioPharm AG was able to reach further goals with respect to the patent protection of MP1032. A far-reaching protection is a crucial factor for the out-licensing and marketing of our substance in the future. Our focus lies on the highly regulated pharmaceutical markets, therefore every patent is not only a proof of quality for our development, but also a crucial factor...

Learn More